1. Articles from Hagenbuchner J , et al.

    1-1 of 1
    1-1 of 1
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    There are no recent topics in the news.

  3. Popular Articles

  4. Picture Gallery

    MRI without contrast agents? Yes, with sugar! New Biomarker Assay Detects Neuroblastoma with Greater Sensitivity Presence of protein important clue to tumour regression in neuroblastoma New biomarker assay detects neuroblastoma with greater sensitivity New research points to potential targeted treatments of neuroblastoma tumours Combining immunotherapies effective against mouse model of cancer Screening Recommendations for Children with Common Cancer Predisposition Syndromes New research points to potential for more targeted treatments of neuroblastoma tumors Telomere study improves understanding of cellular aging and cancer development Giving children a voice in clinical trials NCI-MATCH cancer trial reaches 6,000-patient tumor sequencing goal 2 years early CVD Risk Factors Identified in Long-Term Survivors of Pediatric Cancer